EANS-Adhoc: Ad Hoc Announcement pursuant to para 15 WpHG (German Securities Trading Act) Epigenomics AG: Licensee ARUP Laboratories Launches Septin9 Colorectal Cancer Blood Test in the United State

--------------------------------------------------------------------------------
ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro
adhoc with the aim of a Europe-wide distribution. The issuer is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

New Products/Molecular diagnostics

20.07.2010

Berlin and Seattle, July 20, 2010 - Epigenomics AG (ISIN:
DE000A0BVT96) reports that its licensee ARUP Laboratories, Salt Lake
City, UT, U.S.A., today has announced the launched of a
laboratory-developed test for the blood-based detection of colorectal
cancer. The test is based on Epigenomics' proprietary Septin9
biomarker and DNA methylation technologies non-exclusively licensed
to ARUP in August 2009.

According to ARUP the independently developed and validated Septin9
test identifies nine out of ten people with previously undetected
colorectal cancer, including those with early stage disease. ARUP
states that the test, which is now available to physicians and
patients in the U.S., is not meant to replace colonoscopy but
primarily aims at patients who cannot or will not undergo the
established screening methods.

Founded in 1984, ARUP Laboratories is a national reference laboratory
and an enterprise of the University of Utah and its Department of
Pathology. ARUP offers more than 3,000 tests and test combinations,
ranging from routine screening tests to esoteric molecular and
genetic assays. Clients across the United States include university
teaching hospitals, multihospital groups, major commercial
laboratories, military and other government facilities, as well as
major clinics.

The launch of ARUP's Septin9 test marks another important milestone
in Epigenomics' dual business strategy of direct commercialization
and non-exclusive licensing and partnering of its proprietary
biomarkers and technologies for cancer molecular diagnostics.
Multiple in vitro diagnostic and laboratory-developed blood tests for
the early detection of colorectal cancer based on the Septin9
biomarker have been made available since October 2009 in Europe,
Asia/Pacific and the U.S. by Epigenomics and its partners Abbott
Molecular, Quest Diagnostics, and ARUP Laboratories. Furthermore,
Canadian Warnex Laboratories is working on a laboratory-developed
test for Septin9 that is expected to be launched later this year.

End of Ad hoc

Please find the original press release by ARUP laboratories issued
today at http://www.aruplab.com/AboutARUP/PressRoom/index.jsp

Further, Epigenomics also will issue a press release on the launch of
ARUP's Septin9 test for on Wednesday, July, 21, 2010, 8 am CET. The
release can then be found on Epigenomics website under:
http://www.epigenomics.com/en/Newsroom/Press_Releases/

Epigenomics legal disclaimer. This communication expressly or
implicitly contains certain forward-looking statements concerning
Epigenomics AG and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors which could
cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any
future results, performance or achievements expressed or implied by
such forward-looking statements. Epigenomics AG is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States. The analytical and clinical
performance characteristics of any product based on this technology
which may be sold by Epigenomics at some future time in the U.S. have
not been established.

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Epigenomics AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Epigenomics AG

Dr. Achim Plum

Sen. VP Corporate Development

Tel: +49 30 24345 368

achim.plum@epigenomics.com

Branche: Biotechnology
ISIN: DE000A0BVT96
WKN: A0BVT9
Index: Prime All Share, Technology All Share
Börsen: Frankfurt / regulated dealing/prime standard
Berlin / free trade
Hamburg / free trade
Stuttgart / free trade
Düsseldorf / free trade
München / free trade